Australia's TGA approves Feraccru

RNS Number : 5438R

Shield Therapeutics PLC

09 March 2021

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

Australia's Therapeutic Goods Administration (TGA) approves Feraccru® to treat Iron Deficiency
with or without anaemia in adults

London, UK, 9 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), notes that Australia's Therapeutics Goods Administration has registered Feraccru® in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults.

Feraccru® is already approved in the UK, European Union, Switzerland and United States for the treatment of iron deficiency with or without anaemia in adults. Norgine Pty Ltd will lead all marketing activities in Australia. 

The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for medicinal products ("therapeutic goods").

For further information, please contact:

Shield Therapeutics plc	[phone]
Tim Watts (CEO)
Nominated Adviser and Joint Broker
Peel Hunt LLP			[phone]
James Steel / Christopher Golden
Joint Broker
finnCap Ltd	[phone]
Geoff Nash / Matthew Radley/ Alice Lane
Walbrook PR - Financial PR & IR Adviser		[phone]
Paul McManus / Lianne Cawthorne	or [e-mail]

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com

 

END

 

 

REASSUFMAEFSEDD